ArticleJournal of general internal medicine2025
Disparities in Monoclonal Antibody (mAb) Treatment Usage in the Military Health System During the COVID-19 Pandemic.
Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMonoclonal antibodies (mAbs) were identified in 2020 as potential curative agents for COVID-19, particularly in high-risk populations. However, studies report differences in receipt of mAbs by race, sex, and insurance status. We hypothesized that Military Health System (MHS) beneficiaries, who are universally insured, would have approximately equal uptake of mAbs across sociodemographic categories.
methodsBeneficiaries (active-duty service members, dependents, retirees) aged 12-64, receiving a COVID-19 diagnosis and outpatient treatment between November 9, 2020, and January 24, 2022, were identified from claims data in the MHS Data Repository (MDR). Analyses comprised descriptive statistics on demographics and frequency of COVID-19 mAb treatment for all eligible beneficiaries and by sex, race, sponsor rank, and risk status. Unadjusted and adjusted odds ratios (OR) for likelihood of receiving mAb treatment were obtained using multivariable logistic regression models for all beneficiaries as well as only those classified as "high risk."
resultsOf 221,036 COVID-19 patients receiving outpatient care, 9907 (4.5%) received mAb treatment. Beneficiaries who received treatment were predominately White (53%), female (57%), ages 45-64 (64%), dependents (56%), associated with enlisted rank (77%), and not at high risk of developing severe COVID-19 and/or hospitalization (86%). Greater uptake of mAbs by American Indian/Alaska Native and lesser uptake by Black and Asian compared to White patients, and by female compared to male patients, concurs with published results in the greater US population.
conclusionsDespite universal insurance, significant differences were observed in receipt of mAbs by race, rank (proxy for socioeconomic status), and sex. These results suggest that factors beyond insurance play roles in determining who receives mAbs. The provision of mAbs to non-high-risk patients also suggests a role for either patient- or provider-induced demand. Further research is needed to determine the scope of factors affecting mAb uptake in the MHS, and in other large health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.